A Phase 1/2 interventional study of TLC399 in Central Retinal Vein Occlusion With Macular Edema and Branch Retinal Vein Occlusion With Macular Edema, sponsored by Taiwan Liposome Company. Completed at 6 sites in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-12-23.
Sponsored by Taiwan Liposome Company · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Macular Edema with a site in Taiwan — none open to participants now, none under way, none of them phase 3. Macular Edema · Taiwan.
Among the 18 studies in Macular Edema with a site in Taiwan, this one is the 16th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2014, is the only one in phase 1/2, and was the 5th registered.
758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →None of the 18 studies in Macular Edema with a site in Taiwan is open now. The open studies under Macular Edema, anywhere →
Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 14 · Phase 4 1
First in 2004; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 455 across the 16 interventional studies, 1,359 across the 2 observational. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 18 have an industry lead sponsor. The 9 most frequent:
Taiwan Liposome Company is the lead sponsor of 18 studies on the registry; 1 is open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 4 (57%) have results posted.
Taiwan Liposome Company has 1 study filed under Macular Edema — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Macular Edema with a site in Taiwan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To determine whether TLC399 (ProDex) provides an ideal, safe, long-acting, dexamethasone sodium phosphate (DSP) delivery system for the treatment of macular edema due to retinal vein occlusion (RVO).
\<Part 1> An open-label, sequential dose escalation part to determine the DLT of TLC399 (ProDex) in patients with macular edema due to central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO). The safety results should be evaluated by Safety Monitor Committee regularly every 6 months and after last patient of each cohort completes DLT observation period. The SMC would advise or give permission for further dose escalation, de-escalation, or any study design adjustment. After the study drug administration, these patients will continue to be evaluated for efficacy and safety outcomes up to a period of 12 months unless the patient is withdrawn or discontinues the study.
\<Part 2> An open-label, single-arm design to investigate the use of TLC399 (ProDex) in patients with macular edema due to CRVO or BRVO in one dose level selected from Part 1. The enrollment of subjects for analysis will include approximately 20 patients in total, inclusive of Part 1 and Part 2 for the selected dose group. The safety and efficacy outcomes will be assessed for up to 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TLC399 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP.
Drug: TLC399
TLC399 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP.
Drug: TLC399
TLC399 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP.
Drug: TLC399
TLC399 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP.
Drug: TLC399
Dose-escalation Study from 100 mM PL (20 µL) with 0.24 mg DSP to 100 mM PL (20 µL) with0.36 mg DSP to 100 mM PL (20 µL) with 0.6 mg DSP to 50 mM PL (10 µL) with 0.6 mg DSP.
Also known as: TLC399 (BioSeizer)
Part 1: Dose-limiting Toxicity (DLT)
Ocular AEs
Time frame: 4 weeks
Part 2: Safety Assessment: Number of SAEs and Treatment-related Severe AEs
Number of SAEs and treatment-related severe AEs
Time frame: Up to 1 year
| Milestone | TLC399 (Group 1) | TLC399 (Group R1) | TLC399 (Group 2) | TLC399 (Group 3) |
|---|---|---|---|---|
| Started | 5 | 9 | 0 | 0 |
| Completed | 3 | 7 | 0 | 0 |
| Not completed | 2 | 2 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by sponsor | 1 | 0 | 0 | 0 |
Ocular AEs
| Participants | TLC399 (Group 1) | TLC399 (Group R1) |
|---|---|---|
| Part 1: Dose-limiting Toxicity (DLT) | 1 | 0 |
Number of SAEs and treatment-related severe AEs
| Number of events | TLC399 (Group 1) | TLC399 (Group R1) |
|---|---|---|
| Number of SAE | 2 | 5 |
| Number of Treatment-related severe AE | 0 | 5 |
Collected over 14 days (screeing) + 1 year. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TLC399 (Group 1) | 0/4 (0%) | 2/4 (50%) | 4/4 (100%) |
| TLC399 (Group R1) | 0/9 (0%) | 4/9 (44.4%) | 8/9 (88.9%) |
| Event | TLC399 (Group 1) | TLC399 (Group R1) |
|---|---|---|
| Head Injury With ContusionInjury, poisoning and procedural complications | 1/4 | 0/9 |
| Ocular HypertensionEye disorders | 1/4 | 0/9 |
| Intraocular Pressure IncreasedInvestigations | 0/4 | 1/9 |
| Prolong Vitreous OpacityEye disorders | 0/4 | 1/9 |
| IOP ElevationInvestigations | 0/4 | 1/9 |
| More than 30 Letters Visual Acuity Reduction from Baseline of BCVAEye disorders | 0/4 | 1/9 |
| Increased Intraocular PressureInvestigations | 0/4 | 1/9 |
| Event | TLC399 (Group 1) | TLC399 (Group R1) |
|---|---|---|
| Vitreous opacitiesEye disorders | 4/4 | 6/9 |
| Visual acuity reducedEye disorders | 2/4 | 5/9 |
| Intraocular pressure increasedInvestigations | 0/4 | 5/9 |
| Conjunctival haemorrhageEye disorders | 2/4 | 2/9 |
| Ocular hypertensionEye disorders | 2/4 | 0/9 |
| Visual field defectNervous system disorders | 1/4 | 3/9 |
| Corneal oedemaEye disorders | 1/4 | 1/9 |
| Retinal thickeningEye disorders | 1/4 | 1/9 |
| Abnormal sensation in eyeEye disorders | 1/4 | 0/9 |
| Cataract nuclearEye disorders | 1/4 | 0/9 |
Baseline Analysis Population was based on the Safety Populaiont who exposed to study treatment, either complete or partial.
| Age, Continuous(years) | TLC399 (Group 1) | TLC399 (Group R1) | TLC399 (Group 2) | TLC399 (Group 3) | Total |
|---|---|---|---|---|---|
| Mean | 61.8 ± 10.4 | 65.8 ± 16.2 | — | — | 64.5 ± 14.4 |
| Sex: Female, Male(Participants) | TLC399 (Group 1) | TLC399 (Group R1) | TLC399 (Group 2) | TLC399 (Group 3) | Total |
|---|---|---|---|---|---|
| Female | 4 | 4 | — | — | 8 |
| Male | 0 | 5 | — | — | 5 |
| Race (NIH/OMB)(Participants) | TLC399 (Group 1) | TLC399 (Group R1) | TLC399 (Group 2) | TLC399 (Group 3) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | — | — | 0 |
| Asian | 4 | 9 | — | — | 13 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | — | — | 0 |
| Black or African American | 0 | 0 | — | — | 0 |
| White | 0 | 0 | — | — | 0 |
| More than one race | 0 | 0 | — | — | 0 |
| Unknown or Not Reported | 0 | 0 | — | — | 0 |
| Region of Enrollment(participants) | TLC399 (Group 1) | TLC399 (Group R1) | TLC399 (Group 2) | TLC399 (Group 3) | Total |
|---|---|---|---|---|---|
| Taiwan | 4 | 9 | — | — | 13 |
| Macular edema by retinal vein occlusion(Participants) | TLC399 (Group 1) | TLC399 (Group R1) | TLC399 (Group 2) | TLC399 (Group 3) | Total |
|---|---|---|---|---|---|
| Branch retinal vein occlusion | 3 | 7 | — | — | 10 |
| Central retinal vein occlusion | 1 | 2 | — | — | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2014 to primary completion in Jul 2020, 68 months.
Results were first posted in Dec 2021, 1 year 5 months after primary completion.
Of 16 phase 1/2 interventional studies under Macular Edema, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 68. This study's 68 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone phosphate
Taiwan Liposome Company